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Abstract
Objective: Little is known regarding neuroendocrine responses in adolescent girls with posttraumatic stress disorder (PTSD)
who have experienced sexual abuse. Therefore, we collected saliva samples three times daily for 3 days to assess concen-
trations of salivary alpha amylase (sAA) – a surrogate marker for autonomic nervous system (ANS) activity and, in particular,
sympathetic activity – in sexually abused adolescent girls.
Methods: Twenty-four girls (mean age: 15 – 1.4 years) who had experienced recent sexual abuse (i.e., sexual abuse occurred
1–6 months prior to study enrollment) and 12 healthy comparison subjects (mean age: 14.8 – 1.3 years) completed a structured
interview and assessments to ascertain symptoms of posttraumatic stress, then collected saliva at home upon awakening, 30
minutes after waking, and at 5 p.m. on three consecutive school days.
Results: For sexually abused girls, total PTSD symptoms were associated with higher overall morning levels of sAA
(r[20] = 0.51, p = 0.02), a finding driven by intrusive symptoms (r[20] = 0.43, p < 0.05) and hyperarousal symptoms
(r[20] = 0.58, p = 0.01). There were no significant differences in diurnal sAA secretion between the sexually abused girls and
healthy comparison adolescents.
Conclusions: Overall morning concentrations of sAA in sexually abused girls are associated with overall PTSD severity as
well as symptoms of hyperarousal and intrusive symptoms, possibly reflecting symptom-linked increases in ANS tone. These
data raise the possibility that alterations in ANS activity are related to the pathophysiology of sexual abuse-related PTSD in
adolescent girls, and may inform therapeutic interventions (e.g., antiadrenergic medications).
Introduction
Posttraumatic stress disorder (PTSD) is a common out-come among adolescents with a history of sexual abuse (Co-
peland et al. 2007). Moreover, the autonomic nervous system
(ANS), a collection of central and peripheral neural networks, is
one of several systems responsible for the homeostatic regulation of
stress responses and is implicated in the pathophysiology of PTSD
(Strawn and Geracioti 2008). Specifically, the catecholamine nor-
epinephrine (NE) is elevated in the cerebrospinal fluid of combat
veterans with chronic PTSD, and correlates with the severity of
PTSD symptoms (Geracioti et al. 2001). However, studies of pe-
ripheral (e.g., plasma or urinary) NE have demonstrated mixed
results, with some reports showing elevated levels of NE ( Jensen
et al. 1997), and other studies finding no difference between
patients with and without PTSD (McFall et al. 1992). Similarly, 24
hour urine catecholamine studies have predominantly demon-
strated elevated catecholamine excretion in patients with PTSD
compared with healthy subjects (Yehuda et al. 1998), with some
studies showing no differences (Mellman et al. 1995). In adults
with PTSD, noradrenergic dysfunction (Strawn and Geracioti
2008) likely explains the utility of alpha1 antagonists in the treat-
ment of intrusive symptoms in PTSD.
Hypothalamic pituitary adrenal (HPA) axis change, such as a
blunting of the cortisol awakening response, has been previously
associated with increased severity of posttraumatic stress symptoms
in abused adolescents (Keeshin et al. 2014). In addition, changes in
ANS functioning relatively proximal to the event may predict trauma-
related psychopathology. This is consistent with observations of el-
evated plasma NE levels in children who developed PTSD within
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6 months of a motor vehicle accident (MVA) compared with MVA
survivors without PTSD (Pervanidou et al. 2007). In pediatric sur-
vivors of sexual abuse (regardless of PTSD diagnosis) and in mal-
treated children with PTSD, 24 hour urinary catecholamine excretion
is increased (De Bellis et al. 1994, 1999).
Salivary alpha amylase (sAA), an enzyme produced by the sal-
ivary glands, is widely used as a surrogate marker of ANS tone
(Granger et al. 2007). In this regard, both sympathetic and para-
sympathetic nervous system activity contribute to the secretion of
alpha amylase into saliva, although levels of sAA primarily reflect
sympathetic activity (Bosch et al. 2011). As such, one recent study
suggests that stress-related increases in sAA parallel similar in-
creases in plasma NE concentrations (Nater et al. 2006). The se-
cretion of sAA follows a specific diurnal pattern, with a decrease in
sAA levels in the 30 minutes after awakening, followed by an
increase throughout the remainder of the day. Alterations in the
diurnal pattern of sAA secretion and in acute sAA stress reactivity
abound in adults with chronic stress (Nater et al. 2006) and in adult
refugees with chronic PTSD (Thoma et al. 2012). Young children
exposed to chronic war violence exhibit elevated levels of after-
noon sAA compared with controls (Feldman et al. 2013). In addi-
tion, in contrast to the control group, sAA and cortisol responses to
social stress do not correlate among maltreated and traumatized
adolescents, suggesting an asymmetric functioning of HPA and
ANS activity (Gordis et al. 2008). However, to our knowledge,
diurnal sAA secretion is uncharacterized in pediatric patients who
are at risk for PTSD.
It is unclear whether developmental factors or prior morbidity
and previous experiences of adversity explain the contrasting ANS
findings between adults and children who have experienced trauma
and have symptoms of posttraumatic stress, making it challenging
to apply findings from the adult literature to pediatric populations.
With this in mind, we hypothesized that diurnal concentrations of
sAA would be higher in sexually abused girls than in healthy
comparison girls, and that sAA concentrations would correlate with
severity of symptoms of posttraumatic stress among sexually




This study was a prospectively planned secondary analysis of
salivary analytes collected from abused teenage girls and control
subjects (Keeshin et al. 2014). Sexually abused adolescents (n = 24)
were recruited from an urban children’s advocacy center. Elig-
ibility criteria included not being pregnant, speaking English, and
being a female between the ages of 12 and 17 years who had
experienced forensically substantiated sexual abuse 1–6 months
prior to study enrollment. Families of all patients who met these
criteria were contacted via letter and follow-up phone call, and
interested families participated in a secondary screen before being
invited to participate in the study. Additional criteria covered
during the secondary screen included verifying that the participants
had a normal intelligence quotient (IQ); were postmenarchal; and
had no history of major neurological or medical illness, significant
head trauma, lifetime substance dependence, psychosis, mania, or
PTSD. Additionally, age- and race-matched healthy comparison
subjects were recruited from the community (n = 12) through the
use of posters displayed in the hospital and recruitment emails sent
to all hospital employees. All caregivers with adolescent girls who
met the abovementioned criteria were informed of the details of the
study and invited to participate. Written informed consent was
obtained at the time of the initial study visit by a legal guardian as
well as assent by the participant. Cincinnati Children’s Hospital
Medical Center Institutional Review Board approved the study
protocol.
Demographic and psychometric measurements
Data were obtained from the adolescent and her caregiver(s), and
included age, gender, race, family structure, school placement, and
socioeconomic status. Additionally, caregivers also completed the
Childhood Trust Events Survey (CTES) (Pearl 2000). Symptoms of
PTSD were assessed with the Clinician-Administered PTSD Scale for
Children and Adolescents (CAPS-CA) (Ohan et al. 2002), depressive
symptoms were assessed with the Reynolds Adolescent Depression
Scale-2 (RADS-2) (Osman et al. 2010), dissociative symptoms were
inventoried with the Adolescent Dissociative Experiences Scale
(ADES) (Armstrong et al. 1997), and pubertal status was determined
with the Duke Self-Staging Tanner Scale (Duke 1980).
CTES. CTES (Pearl, 2000) assesses previous accidental,
community, and interpersonal adversities. The CTES is a 26 item
measure that records whether or not different adversities occurred
sometime in childhood. The possible responses (‘‘yes,’’ ‘‘no,’’ and
‘‘don’t know’’) to each question are provided by the caregiver, and
this instrument does not weight the frequency or duration of ad-
verse experiences. The 26 items included in the measure are
composed of 15 potentially traumatic events that could be life
threating or result in serious injury, and 11 additional adversities
commonly experienced by children.
CAPS-CA. CAPS-C, a structured interview that obtains de-
tailed histories of specific traumatic events, and assesses both fre-
quency and intensity of currently experienced symptoms, was used
to assess PTSD symptoms. The instrument is aligned with Diag-
nostic and Statistical Manual of Mental Disorders, 4th ed., Text
Revision (DSM-IV-TR) PTSD symptoms and has high reliability,
ranging from 0.92 for frequency and 0.98 for intensity ratings and
strong internal consistency with alphas ranging from 0.85 to 0.87
for the three symptom clusters of PTSD as described in DSM IV TR
(American Psychiatric Association 2000).
RADS-2. RADS-2 is a 30 item self-report measure intended
for children ‡ 11 years of age that examines different aspects of
depression, including dysphoric mood, anhedonia, negative self-
evaluation and, somatic complaints. The RADS-2 has an internal
consistency of 0.92 and a test–retest reliability of 0.89.
ADES. ADES, a 30 item self-report, assesses both deperson-
alization and derealization dissociative symptoms. Symptom fre-
quency is rated on a scale of 0 to 10, with 10 signifying that the
symptom happens all the time. Prior studies have demonstrated that
scores of 3.7 suggest clinically significant dissociation.
Saliva collection
Participants were instructed to collect saliva samples at waking,
30 minutes after awakening and between 4 and 6 p.m. for 3 school
days. They were instructed to swallow, think about a favorite food,
sublingually place the oral swab, and maintain the swab in that
position for 2 minutes without chewing. After 2 minutes, the oral
swab was removed from the mouth and placed in a prelabeled
swab storage tube and frozen. Participants were provided detailed,
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step-by-step instructions, practiced saliva collection during the
research visit until they felt comfortable performing the process
independently, and were provided contact information regarding
whom to contact if there was a question regarding saliva collection.
Saliva samples were collected at least 60 minutes after any con-
sumption of food or strenuous physical activity. Samples were col-
lected using 1 · 4 cm absorbent synthetic oral swabs (Salimetrics,
State College, PA). When requested, families were contacted (via
text messaging or phone calls) to ensure that the morning and af-
ternoon samples were collected. All participants documented saliva
collection times on a log sheet.
In addition, participants indicated the presence of one or more
sleep difficulties the evening prior to the morning saliva collection
(unable to fall asleep, waking up during the night, nightmares,
constantly going to the bathroom, and other disturbances). Samples
were stored in the participant’s freezer until the research team re-
trieved all samples, at which point the samples were stored at
- 80C until processing. Samples were assayed for sAA in singlet
using a kinetic reaction assay, without modifications to the manu-
facturer’s recommended protocol (Salimetrics, State College, PA).
The assay utilized 10 lL of saliva, and the lower limit of detection
was 0.4 U/mL, with an average interassay coefficient of variation
< 10%. For each sample, we determined raw sAA levels (in U/mL)
and salivary flow rate (mL/min).
Analytic strategy
For each of the 3 collection days, the sAA awakening response
was calculated as the difference between the 30 minute postwaking
value and the waking value. For the diurnal slope (i.e., the change in
sAA occurring from the 30 minute postwaking to the afternoon
sample), a linear regression was fitted for each day, predicting sAA
levels from time since waking. Finally, we calculated averages for
awakening levels, 30 minute postwaking levels, overall morning
levels (i.e., first and second samples), and afternoon levels across
collection days. All diurnal sAA measures were calculated using
the raw, untransformed sAA levels.
We determined the association (Spearman rho) between raw sAA
levels (in U/mL) and salivary flow rate (mL/min). In addition, we
examined whether sleep duration and reported sleep problems were
associated with diurnal sAA on each collection day using Mann–
Whitney U tests and Spearman rho correlations. Then, for each
participant, the diurnal measures were averaged across collection
days. The average for each measure was based on 3 collection days
for 100% (afternoon alpha amylase) and 78% (overall morning al-
pha amylase and diurnal change) of the sample. Reasons for missing
data were insufficient specimen volume, extremely high sAA levels
( > 1000 U/mL), or because the second sample was not collected 25–
35 minutes after the first sample. A square root transformation was
sufficient to correct for the skewed distribution of the diurnal slope,
sAA levels at 30 minutes postwaking and afternoon sAA levels, as
well as for prior adversities and prior potentially traumatic experi-
ences. In addition, one outlier for 30 minutes postwaking and for
afternoon sAA levels was winsorized (i.e., recoded to the next
highest value in the distribution) (Tabachnick and Fidell 2000). A
log transformation was applied to dissociative experiences. As three
girls were on medications that could affect levels of sAA, we en-
tered medication use as a covariate.
For the main analyses, analyses of (co)variance (ANCOVA)
were used to test differences in trauma-related symptoms (overall
PTSD severity of symptoms, as well as individual criterion sub-
scales as delineated in the CAPS-CA; intrusive symptoms, avoidant
symptoms, and hyperarousal symptoms), sleep duration and diffi-
culties (the presence of one or more sleep disturbances the prior
night), and diurnal sAA between the abused and control groups
(controlling for medication use in the analyses for diurnal sAA).
We also calculated partial correlations and ANCOVAs to examine
the associations among PTSD, depressive, and dissociative symp-
toms with individual differences in diurnal sAA within the abused
group, again controlling for medication use.
Results
Descriptive statistics
In Tables 1 and 2, means, medians, and standard deviations are
reported separately for the abused girls and the girls from the
control group. Problems with sleep (defined as reporting at least one
sleep difficulty during the 3 study days) were more common in the
abused group than in the healthy controls (88% vs. 50%, v2 = 6,
p < 0.01). Across all participants, there were no significant associ-
ations between sleep duration and diurnal sAA for any of the col-
lection days ( p = 0.18–0.98). Similarly, reported sleep problems
were not associated with diurnal sAA on any of the collection days
( p = 0.11–0.99), with the exception of the diurnal slope on day 3,
which was significantly higher for girls who reported sleep prob-
lems during the preceding night than for girls who did not report
sleep problems ( p = 0.04). Spearman rho correlations showed that
for all samples, salivary flow rate was not significantly associated
with sAA levels (Spearman rho = - 0.30–0.24, p = 0.12–0.97) and,
therefore, sAA levels were not corrected for flow rate.
Table 1. Descriptive Statistics for Sexually













Breast stage 3.9 – 0.7 4.4 – 0.6*
Genital stage 4.2 – 0.4 4.3 – 0.8
Months since abuse - 3.2 – 1.6
Prior adversities 0.7 – .8 3.3 – 1.9**
Prior potentially traumatic eventsa 0.4 – .5 2.4 – 2.1**
Depressive symptoms 37.7 – 4.7 50.8 – 10**
Dissociative experiences (log) 0.4 – 0.2 0.9 – 0.5**
PTSD symptom severity
(CAPS-CA score)
Intrusive recollection 1.0 – 2.7 10.4 – 7.7**
Avoidant/numbing 1.9 – 2.4 15.8 – 9.7**
Hyperarousal 3.6 – 3.4 16.1 – 7.8**
Total CAPS-CA score 6.5 – 6.6 42.3 – 22.5**
Means are reflected – their standard deviations.
aAny trauma reported in healthy controls did not meet A2 criterion for
DSM-IV-TR PTSD (i.e., did not involve intense fear, helplessness, horror, or
agitation) and reported minimal to no trauma symptoms on the CAPS-CA.
*p < 0.05, **p < 0.01.
PTSD, posttraumatic stress disorder; CAPS-CA, Clinician-Administered
PTSD Scale for Children and Adolescents; DSM-IV-TR, Diagnostic and
Statistical Manual of Mental Disorders, 4th ed., Text Revision.
Adapted from Keeshin et al. 2014.
346 KEESHIN ET AL.
Prior adversities were significantly more common among the
abused girls than the healthy comparison participants (3.3 + 1.9 vs.
0.7 + 0.8, p < 0.001). Specific prior childhood adversities that were
most common among the abused girls were unexpected deaths in the
family (63%), caregiver depression or mental illness (54%), and ex-
periencing bullying outside of the home (54%). In contrast, the most
common adversities among the comparison subjects were medical
procedures (25%) and unexpected deaths in the family (25%). None
of the comparison subjects reported any significant current or prior
distress related to their prior adversities and none of these experiences
met criteria A1 or A2 criteria for PTSD (i.e., abuse or serious and life-
threatening violence). Among the 24 sexually abused adolescents, all
adolescents experienced their most recent episode of sexual abuse
1–6 months prior to participation in the study. Two of the girls in the
study experienced episodes of sexual abuse prior to the 1–6 month
window, and on average, sexually abused adolescents had experi-
enced 2.4 lifetime potentially traumatic events, which was signifi-
cantly more than the comparison subjects’ average of 0.4 (Table 1).
Age of onset of prior sexual abuse and potentially traumatic events
were not collected as part of the study.
Differences in diurnal sAA between abused
and healthy comparison subjects
ANCOVAs were conducted to examine differences in diurnal
sAA between the abused group and the nonabused, healthy com-
parison girls; medication use was entered as a covariate. Compared
with the healthy girls, survivors of sexual abuse did not differ in
terms of absolute values of sAA at awakening (F [1, 33] = 0.03,
p = 0.86) and 30 minutes after waking (F [1,33] = 0.39, p = 0.54), in
overall morning levels (i.e., average of the first and second samples;
F [1,32] = 0.17, p = 0.68) and in afternoon levels (F [1, 33] = 0.01,
p = 0.93) (Table 2). In addition, there were no significant differ-
ences between the abused and control groups for the awakening
response (F [1,32] = 0.01, p = 0.93) or the increase in sAA levels
across the day (F [1,33] = 0.35, p = 0.56).
Associations between trauma-related symptoms
and diurnal sAA in abused girls
Partial correlations among the diurnal sAA measures and PTSD,
and depressive and dissociative symptoms in abused girls, con-
trolling for medication use, are shown in Table 3. When we ex-
amined partial correlations between trauma-related symptoms and
sAA levels at different time points across the day, the association
with dissociative experiences was significant for afternoon levels (r
[21] = 0.49, p = 0.02). PTSD symptoms were not related to sAA
morning awaking response or change in sAA throughout the day.
However, PTSD symptoms were associated with higher overall
morning levels (r [21] = 0.51, p < 0.01) (Fig. 1), which appeared to
be driven by hyperarousal (r [20] = 0.58, p < 0.01) and intrusive
symptoms (r [20] = 0.43, p < 0.05).
Discussion
To our knowledge, this is the first study to assess the relationship
between diurnal sAA and PTSD-related symptomatology, con-
trolling for duration and type of most recent trauma. Here, we have
observed that sAA concentrations, in a cohort of sexually abused
adolescent girls, were directly related to the severity of PTSD
symptoms. sAA concentrations were examined at three time points
over 3 consecutive days, and were associated with symptom se-
verity among the sexually abused girls, which may be an early
indicator of ANS dysregulation, and relate to the pathoetiology of
PTSD symptoms.
In our cohort of sexually abused adolescent girls, the severity of
PTSD symptoms correlated with overall morning sAA concentra-
tions. Importantly, this complements findings by Feldman and
others that saw increases in afternoon sAA among war- exposed
young children, and this contrasts with findings related to sAA in
adults with chronic PTSD, wherein changes in the sAA awakening
response but not in absolute morning values of sAA are observed
(Thoma et al. 2012). Other markers of stress, especially cortisol,
have also demonstrated different properties when measured in
children and adults with PTSD, which may be a factor of
Table 2. Descriptive Statistics for Diurnal sAA (U/mL, Untransformed) for Abused Girls and Control Girls
Control (n = 12) Abused (n = 23–24)
Mean Median SD Mean Median SD
Diurnal sAA
Levels at awakening 75.82 62.35 43.82 70.50 60.95 44.27
Levels 30 postwaking 51.08 40.79 25.12 54.86 31.53 64.64
Morning levels 64.33 64.32 22.71 55.50 47.62 36.91
Levels in the afternoon 92.66 86.77 38.98 107.21 77.47 102.47
Awakening response - 26.51 - 39.96 54.77 - 22.99 - 14.10 35.34
Diurnal slope 3.92 3.44 3.17 5.49 4.29 5.23
sAA, salivary alpha amylase.
Table 3. Partial Correlations for the Abused
Group Between Diurnal sAA Variables
and Previous Traumatic Experiences, Depression,
Dissociative Experiences and PTSD Symptoms,







Months since abuse 0.12 0.09 0.31
Previous traumas 0.14 0.19 0.12
Depressive symptoms 0.40 0.01 0.35
Dissociative experiences 0.29 0.17 0.49*
PTSD symptoms
Intrusive recollection 0.43* - 0.05 0.33
Avoidant/numbing 0.37 - 0.15 0.23
hyperarousal 0.58* - 0.14 0.25
Total score 0.51* - 0.13 0.29
*p < 0.05. Degrees of freedom ranged between 20 and 21.
sAA, salivary alpha amylase; PTSD, posttraumatic stress disorder.
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development and/or time since exposure to trauma (Trickett et al.
2010). In our study, we did not observe a significant difference in
afternoon levels of sAA between high- and low-symptom girls,
which is similar to the findings by Thoma and colleagues, sug-
gesting the potential importance of collection time to the utility of
sAA measurements in this population.
The results of studies evaluating nonsalivary peripheral NE have
yielded conflicting results with regard to the prognostic value of NE
as a biomarker for trauma-related psychopathology, and plasma
concentrations of NE may poorly reflect central noradrenergic tone
in PTSD (Geracioti et al. 2001). Our study demonstrates an asso-
ciation between severity of PTSD and overall morning sAA. This
finding is similar to other findings among children with acute PTSD,
in which morning plasma NE levels were elevated in children with
PTSD compared to MVA survivors who did not develop PTSD
(Pervanidou and Chrousos 2007), and in which there were no dif-
ferences noted in afternoon NE levels between PTSD and non-
PTSD traumatized children. In addition, the elevations in sAA are
consistent with studies demonstrating increases in 24 hour ca-
techalomine excretion in pediatric PTSD (De Bellis et al. 1999).
The findings associating dissociative symptoms and sAA are
intriguing. Previous studies have demonstrated negative correla-
tions between urinary NE and dissociative symptoms in adults
without PTSD (Simeon et al. 2003) as well as in traumatized adults
in the peritraumatic period (Delahanty et al. 2003). Our study
demonstrates a positive correlation between current dissociative
symptomatology and sAA concentrations among traumatized ad-
olescents. This may represent an independent association between
sAA and dissociation, or may represent syndromic overlap, with a
strong correlation between ADES and CAPSCA total scores pres-
ent among the abused girls in the current study (r [22] = 0.66,
p < 0.01). These findings regarding dissociation may be of partic-
ular relevance, given the new dissociative subtype specifier of
PTSD as described in Diagnostic and Statistical Manual of Mental
Disorders, 5th ed. (DSM-V), based on the evidence that PTSD with
dissociation is not only clinically different than nondissociative
PTSD, but also has different underlying biological features (Lanius
et al. 2010; American Psychiatric Association 2013).
Cognitive behavioral therapies are the first line treatment for
traumatized children and adolescents (Keeshin and Strawn 2014);
FIG. 1. Scatterplots of the Clinician Administered Posttraumatic Stress Scale for Children and Adolescents (CAPS-CA) score, and
morning levels of salivary alpha amylase (sAA) (U/mL) in abused adolescent girls. Significant associations between morning sAA and
CAPS-CA symptom severity were observed for total posttraumatic stress disorder (PTSD), intrusive, and hyperarousal symptoms, but
not for avoidance symptoms. Girls who were treated with medications were excluded in these figures.
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however, not all benefit from such interventions. Pharmacologi-
cally, adrenergic modulating agents have demonstrated efficacy in
reducing or ameliorating nighttime disturbances in adults with
PTSD. Specifically, prazosin has demonstrated efficacy in the re-
duction of nighttime symptoms in multiple randomized control
trials in adults (Kung et al. 2012) and in case reports in children
(Strawn and Keeshin 2011). Other antiadrenergic agents commonly
used in the pediatric population, such as guanfacine and clonidine,
have demonstrated mixed results in the treatment of PTSD (Kee-
shin and Strawn 2014). Future research that incorporates proxies
for ANS, such as sAA, may provide a more complete understanding
of underlying pathophysiological changes associated with PTSD
and treatment response, stratifying children who would most ben-
efit from different treatment modalities as well as opening up new
areas of clinical investigation.
Limitations
Although this is the first study of diurnal sAA in sexually
abused adolescents, there are several limitations. The ANS op-
erates in concert with other stress response systems that have
been implicated in the pathophysiology of PTSD and changes in
the hypothalamic pituitary adrenal axis including corticotropin-
releasing hormone (CRH) (Geracioti et al. 2008) and cortisol
(Yehuda et al. 2002) have been demonstrated in both stressed and
nonstressed studies, and may moderate the observed results. As an
example, maltreated children with internalizing symptoms dem-
onstrated a blunting of expected diurnal decrease in cortisol
throughout the day, suggesting changes in the HPA-axis that may
be related to changes in the ANS (Cicchetti et al. 2010). Because
NE is involved in HPA-axis function and hemostasis, examina-
tion of normal and potential aberrations regarding interaction and
negative as well as positive feedback between these two systems
may be informative. Second, the sample is relatively small, and
does not allow for extensive analysis of covariates that may help
explain the observed findings. Third, saliva was collected in the
subjects’ homes and not in a standardized laboratory setting, al-
though this approach was chosen to minimize secondary stress
effects associated with travel to the clinical research setting, and
both parents and participants were trained and were required to
demonstrate competency in appropriate salivary collection, and
all participants documented the timing and duration of saliva
collection at home. Finally, although we focused on a relatively
brief time period post-abuse, it is possible that dynamic changes
in ANS function occur over that time period with relation to
symptom severity, and we are underpowered to detect any time by
symptom interaction effects.
Conclusions
Adolescent girls with a history of sexual abuse demonstrated a
correlation between levels of sAA and symptoms of posttraumatic
stress. Overall morning elevation of sAA in sexually abused girls
appears to be associated with PTSD symptomatology as well as
intrusive symptoms and hypervigilance, reflecting alterations in
the ANS, and possibly increased sympathetic tone. In addition,
dissociative symptoms may be related to afternoon levels of sAA,
reflecting a potentially different biological profile within trau-
matized individuals who have dissociative symptomatology.
Clinical Significance
These data raise the possibility that alterations in the dynamic
secretion of sAA are directly related to the pathophysiology of
sexual abuse-related PTSD symptoms in adolescent girls, and that
investigation into the utility of antiadrenergic agents for the treat-
ment of pediatric PTSD is warranted.
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